Corrected: Northwest Bio drug for inoperable tumors safe so far -researcher

Northwest Biotherapeutics

19/06/2014 21:28

(Corrects name of company in first paragraph) 
    June 19 (Reuters) - An experimental Northwest 
Biotherapeutics Inc  NWBO.O  drug for inoperable tumors has 
shown no signs of toxicity in an ongoing safety trial being 
conducted at M.D. Anderson Cancer Center, the trial's researcher 
said on Thursday. 
    "We are testing for toxicity, and we haven't seen any 
toxicity" from the drug so far, Dr. Vivek Subbiah, an oncologist 
who is conducting the DCVax-Direct studies at the prominent 
Houston center, told Reuters. The trials have been underway 
since last autumn. 
    Investigators at the hospital and at several other research 
sites are testing whether DCVax-Direct can successfully treat a 
wide range of solid tumors so advanced or inaccessible that they 
are deemed inoperable. 
    The ongoing first phase of the study is focusing on whether 
the injectable drug is safe. The primary goal of a subsequent 
Phase II part of the study, if the drug proves safe, would 
assess whether it can actually shrink or eliminate tumors. 
       
 
 (Reporting by Ransdell Pierson) 
 ((ransdell.pierson@thomsonreuters.com)(646 223 6030)(Reuters 
Messaging: ransdell.pierson.thomsonreuters.com@reuters.net)) 
 
Keywords: NORTHWEST BIO SAFETY/